About
Josh Bilenker serves as a Partner of Aisling Capital. Previously, Josh Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Josh Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Josh Bilenker currently serves as a director of LensAR, Inc., Roka Bioscience, Inc., T2 Biosystems and ViewRay, Inc and as a board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise. Josh Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.Previously, Josh Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains a Venture Partner. From
Position in the VCSift Database
- • 2 investors at Loxo Oncology are tracked.
- • 44 investors hold the Founder, President & CEO role in VCSift. Josh Bilenker is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Josh
Search Investors